Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Gilead Settles Teva HIV Drug Patent Suit to Avoid Trial
Bloomberg
Wednesday, February 20, 2013 - 12:05pm
tags:
Teva, patents, HIV, Gilead, Viread, hepatitis B
Pfizer Asks Court To Overturn Generic Injury Ruling
Pharmalot
Wednesday, February 20, 2013 - 11:56am
tags:
generics, Pfizer, Reglan
Novabay: A Novel Agent Against A Common Problem
Seeking Alpha
Wednesday, February 20, 2013 - 11:55am
tags:
NovaBay Pharmaceuticals, NVC-422, antibiotics
Medicines Co.'s 4Q profit grows 5 percent
Yahoo/AP
Wednesday, February 20, 2013 - 11:52am
tags:
Medicines Company, earnings
The War Over Amarin: Feuerstein Battles Heisenberg And How I'd Invest It
Seeking Alpha
Wednesday, February 20, 2013 - 11:51am
tags:
Amarin, Celsion
Allergan’s Botox Put Boy on Respirator, Lawyer Tells Jury
Bloomberg
Wednesday, February 20, 2013 - 11:49am
tags:
Allergan, Botox, misbranding, off-label
Pharmacyclics Valuation Jumps Over $1 Billion On Newest Developments
Seeking Alpha
Wednesday, February 20, 2013 - 11:48am
tags:
Pharmacyclics, JNJ
Elite Pharmaceuticals' CEO Discusses F3Q13 Results - Earnings Call Transcript
Seeking Alpha
Wednesday, February 20, 2013 - 11:47am
tags:
earnings, Elite Pharmaceuticals
A Strong Growth Opportunity In Multiple Sclerosis
Motley Fool
Wednesday, February 20, 2013 - 11:46am
tags:
multiple sclerosis, MS, Elan, Biogen Idec, Tysabri, Teva, XenoPort, Sanofi, BG-12
GlaxoSmithKline Offers A High Dividend, But I Think It's Unsustainable
Seeking Alpha
Wednesday, February 20, 2013 - 11:42am
tags:
dividends, GSK
Is Eli Lilly Being Wise About YZ?
Motley Fool
Wednesday, February 20, 2013 - 11:42am
tags:
Eli Lilly
Can Zytiga Build on a Historic 2012?
Motley Fool
Wednesday, February 20, 2013 - 11:40am
tags:
Zytiga, JNJ, prostate cancer
Will Isis Right Pfizer's Wrong?
Motley Fool
Wednesday, February 20, 2013 - 11:33am
tags:
Pfizer, Isis Pharmaceuticals, Kynamro, generics
Ziopharm: What Happens Next?
Seeking Alpha
Tuesday, February 19, 2013 - 3:28pm
tags:
Ziopharm, palifosfamide
FDA OKs Novartis Drug to Fight Liver Transplant Rejection
Motley Fool
Tuesday, February 19, 2013 - 3:25pm
tags:
liver transplant, Novartis, FDA, Zortress
Gilead hepatitis C drug meets goal of 4th late-stage study
Reuters
Tuesday, February 19, 2013 - 3:24pm
tags:
hepatitis C, Gilead, sofosbuvir
J&J Jury Begins Deliberating in First Vaginal Mesh Trial
Bloomberg
Tuesday, February 19, 2013 - 3:15pm
tags:
JNJ, vaginal mesh
BioMarin Earnings: An Early Look
Motley Fool
Tuesday, February 19, 2013 - 3:14pm
tags:
earnings, Biomarin
Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge
Yahoo
Tuesday, February 19, 2013 - 10:18am
tags:
stem cells, Osiris Therapeutics, patents, Prochymal
Amgen's Future Is Brighter Than You Might Think
Motley Fool
Tuesday, February 19, 2013 - 10:13am
tags:
Amgen

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.